| 2015-07 |
Established Susmed LLC in Bunkyo-ku, Tokyo |
| 2016-02 |
Organizational change to Kabushiki Kaisha (Corporation) |
| 2016-09 |
Started clinical trials for insomnia treatment app at two domestic facilities |
| 2017-08 |
Headquarters relocation (2-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo, Nihonbashi Life Science Building 2) |
| 2019-02 |
Start of DTx development support services |
| 2019-05 |
Provision of machine learning automatic analysis system |
| 2019-07 |
Selected for the |
| 2019-12 |
Headquarters relocation (5th floor, Nihonbashi Honcho 3-chome Building, 3-8-5 Nihonbashi Honcho, Chuo-ku, Tokyo) |
| 2020-05 |
Entered into a capital and business alliance agreement with Suzuken Co., Ltd. |
| 2020-08 |
Entered into a capital and business alliance agreement with Sumitomo Corporation and Nippon Chemifa Corporation. |
| 2020-09 |
Entered into a capital and business alliance agreement with Sawai Pharmaceutical Co., Ltd. |
| 2020-10 |
Entered into a business alliance agreement with CIMIC Inc. for the development support of digital therapy. |
| 2020-12 |
Approval by the Ministry of Economy, Trade and Industry and the Ministry of Health, Labour and Welfare for "Monitoring work replacement using blockchain technology". |
| 2021-02 |
Started joint development of a treatment app for chronic kidney disease patients with Tohoku University and the Japan Kidney Rehabilitation Society. |
| 2021-06 |
Entered into a business alliance agreement with EPS Holdings Inc. to improve the efficiency of clinical trial operations using blockchain technology. |
| 2021-10 |
Headquarters relocation (10th floor, Nihonbashi Honcho Showa Street Building, 3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo) |
| 2021-10 |
Relocated headquarters (10th floor, Nihonbashi Honcho Showa-dori Building, 3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo) |
| 2021-11 |
Achieved primary endpoints in domestic verification trial of insomnia disorder treatment app |
| 2021-12 |
Listed on Tokyo Stock Exchange Mothers Market |
| 2021-12 |
Signed sales partnership agreement with Shionogi & Co., Ltd. regarding insomnia disorder treatment app |
| 2022-04 |
Transitioned from Mothers Market to Growth Market due to review of Tokyo Stock Exchange market classification |
| 2022-05 |
Started research and development on clinical data processing methods and quality assurance to promote data utilization with the National Center of Neurology and Psychiatry |
| 2022-06 |
Signed business consignment agreement with Akuris Pharma Inc. for the world's first clinical trial utilizing blockchain technology |
| 2022-11 |
Signed contract with Kyorin Pharmaceutical Co., Ltd. for joint research, development, and sales of treatment apps in the otolaryngology field |
| 2023-02 |
Obtained manufacturing and sales approval for insomnia disorder application |
| 2023-09 |
Signed basic agreement with Tohoku University to promote the use of real-world data (RWD) of medical devices utilizing blockchain technology |
| 2023-09 |
Signed contract with Asuka Pharmaceutical Co., Ltd. for joint research, development, and sales of treatment apps in obstetrics and gynecology |
| 2024-02 |
Approved as a designated research institution for the Grant-in-Aid for Scientific Research by the Ministry of Education, Culture, Sports, Science and Technology |
| 2024-09 |
Transitioned to a company with an Audit & Supervisory Committee |
| 2025-09 |
Obtained approval for partial change of manufacturing and sales approval for insomnia disorder app |
| 2026-05 |
Insurance coverage for insomnia disorder app approved |
